Clinical Outcomes and Prognostic Factors of Salvage Stereotactic Body Radiotherapy for Post-Surgical Thoracic Oligo-Recurrence/Metastasis of Non-Small-Cell Lung Cancer

References

• Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC.. Transl Lung Cancer Res. 2014;3(4):4. doi:10.3978/j.issn.2218-6751.2013.12.05
   Google Scholar
• Hung -J-J, Jeng W-J, Hsu W-H, Chou T-Y, Huang B-S, Wu Y-C. Predictors of Death, local recurrence, and distant metastasis in completely resected pathological stage-i non–small-cell lung cancer. J Thorac Oncol. 2012;7(7):1115–1123. doi:10.1097/JTO.0b013e31824cbad822592210
   PubMed Web of Science ®Google Scholar
• Sekihara K, Hishida T, Yoshida J, et al. Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is ‘cured’ from postoperative recurrence? Eur J Cardiothorac Surg. 2017;52(3):522–528. doi:10.1093/ejcts/ezx12728482033
   PubMed Web of Science ®Google Scholar
• Matsuguma H, Nakahara R, Wakamatsu I, et al. Definitive local therapy for oligo-recurrence in patients with completely resected non–small cell lung cancer. Am J Clin Oncol. 2020;43(3):210–217. doi:10.1097/COC.000000000000065631850917
   PubMed Web of Science ®Google Scholar
• Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82(2):2. doi:10.1016/j.lungcan.2013.07.026
   Web of Science ®Google Scholar
• Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non–small-cell lung cancer. Clin Lung Cancer. 2014;15(5):5. doi:10.1016/j.cllc.2014.04.003
   Web of Science ®Google Scholar
• Juan O, Popat S. Ablative therapy for oligometastatic non–small cell lung cancer. Clin Lung Cancer. 2017;18(6):6. doi:10.1016/j.cllc.2017.03.002
   Web of Science ®Google Scholar
• Petrelli F, Ghidini A, Cabiddu M, et al. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: a systematic review and meta-analysis.. Lung Cancer. 2018;126:126. doi:10.1016/j.lungcan.2018.11.017
   Web of Science ®Google Scholar
• Yuan Q, Wang W, Zhang Q, Wang Y, Chi C, Xu XC. <p>Clinical Features and Prognostic Factor of Thoracic Postoperative Oligo-Recurrence of Non-Small-Cell Lung Cancer. Cancer Manag Res. 2020;12:1397–1403. doi:10.2147/CMAR.S23057932158271
   PubMed Web of Science ®Google Scholar
• Terada Y, Isaka M, Harada H, et al. Radiotherapy for local recurrence of non-small-cell lung cancer after lobectomy and lymph node dissection—can local recurrence be radically cured by radiation? Jpn J Clin Oncol. 2020;50(4):425–433. doi:10.1093/jjco/hyz18831926488
   PubMed Web of Science ®Google Scholar
• Milano MT, Kong F-MS, Movsas B. Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy. Transl Lung Cancer Res. 2018;8(1):78–87. doi:10.21037/tlcr.2018.08.15
   Web of Science ®Google Scholar
• Ning MS, Gomez DR, Heymach JV, Swisher SG. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease. Transl Lung Cancer Res. 2018;8(1):97–106. doi:10.21037/tlcr.2018.09.21
   Web of Science ®Google Scholar
• Timmerman RD, Paulus R, Pass HI, et al. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol. 2018;4(9):1263–1266. doi:10.1001/jamaoncol.2018.125129852037
   PubMed Web of Science ®Google Scholar
• Shen Z-T, Wu X-H, Li B, Zhu -X-X. Clinical outcomes of CyberKnife stereotactic body radiotherapy for peripheral stage I non-small cell lung cancer. Med Oncol. 2015;32(3):55. doi:10.1007/s12032-015-0506-125638468
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-071315534099
   PubMed Web of Science ®Google Scholar
• Takeda A, Sanuki N, Eriguchi T, et al. Salvage stereotactic ablative irradiation for isolated postsurgical local recurrence of lung cancer. Ann Thorac Surg. 2013;96(5):1776–1782. doi:10.1016/j.athoracsur.2013.06.01423998410
   PubMed Web of Science ®Google Scholar
• Agolli L, Valeriani M, Carnevale A, et al. Role of salvage stereotactic body radiation therapy in post-surgical loco-regional recurrence in a selected population of non-small cell lung cancer patients. Anticancer Res. 2015;35(3):457.25550587
   PubMed Web of Science ®Google Scholar
• Aoki S, Yamashita H, Takahashi W, et al. Salvage stereotactic body radiotherapy for post-operative oligo-recurrence of non-small cell lung cancer: a single-institution analysis of 59 patients.. Oncol Lett. 2020;19(4):2695–2704. doi:10.3892/ol.2020.1140732218820
   PubMed Web of Science ®Google Scholar
• Hishida T, Nagai K, Yoshida J, et al. Is surgical resection indicated for a solitary non–small cell lung cancer recurrence? J Thorac Cardiovasc Surg. 2006;131(4):838–842. doi:10.1016/j.jtcvs.2005.11.02816580442
   PubMed Web of Science ®Google Scholar
• Han SJ, Cho S, Yum S, Kim K, Jheon S. Surgical treatment of pulmonary oligorecurrence after curative resection for non-small-cell lung cancer. Interact Cardiovasc Thorac Surg. 2020;30(1):18–23. doi:10.1093/icvts/ivz22131539023
   PubMed Web of Science ®Google Scholar
• White A, Kucukak S, Lee DN, et al. Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer. J Thorac Dis. 2020;12(3):217–222. doi:10.21037/jtd.2020.01.5132274087
   PubMed Web of Science ®Google Scholar
• Xiong W, Xu Q, Xu Y, et al. Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects. BMC Cancer. 2014;14(1):719. doi:10.1186/1471-2407-14-71925260301
   PubMed Web of Science ®Google Scholar
• Sun B, Brooks ED, Komaki R, et al. Long-term outcomes of salvage stereotactic ablative radiotherapy for isolated lung recurrence of non–small cell lung cancer: a phase ii clinical trial. J Thorac Oncol. 2017;12(6):983–992. doi:10.1016/j.jtho.2017.02.01828259750
   PubMed Web of Science ®Google Scholar
• Song IH, Yeom SW, Heo S, et al. Prognostic factors for post-recurrence survival in patients with completely resected Stage I non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(2):262–267. doi:10.1093/ejcts/ezt33323811122
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.02428838390
   PubMed Web of Science ®Google Scholar
• Hirahara T, Arigami T, Yanagita S, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19(1):672. doi:10.1186/s12885-019-5903-y31286873
   PubMed Web of Science ®Google Scholar
• Cannon NA, Meyer J, Iyengar P, et al. Neutrophil–Lymphocyte and Platelet–lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non–small-cell lung cancer. J Thorac Oncol. 2015;10(2):280–285. doi:10.1097/JTO.000000000000039925299234
   PubMed Web of Science ®Google Scholar
• Guo D, Li M, Chen D, et al. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Future Oncol. 2019;15(6):625–635. doi:10.2217/fon-2018-066730430864
   PubMed Web of Science ®Google Scholar
• Sebastian N, Wu T, Bazan J, et al. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.. Radiother Oncol. 2019;134:151–157. doi:10.1016/j.radonc.2019.01.03231005209
   PubMed Web of Science ®Google Scholar
• Hsu BE, Shen Y, Siegel PM. Neutrophils: orchestrators of the Malignant Phenotype. Front Immunol. 2020;11:1778. doi:10.3389/fimmu.2020.0177832849639
   PubMed Web of Science ®Google Scholar
• Ethier J-L, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2. doi:10.1186/s13058-016-0794-128057046
   PubMed Web of Science ®Google Scholar
• Zhao Y, Rahmy S, Liu Z, Zhang C, Lu X. Rational targeting of immunosuppressive neutrophils in cancer. Pharmacol Ther. 2020;212:107556. doi:10.1016/j.pharmthera.2020.10755632343986
   PubMed Web of Science ®Google Scholar
• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer.. JAMA. 2010;303(11):11. doi:10.1001/jama.2010.261
   Web of Science ®Google Scholar
• Chang JY, Li -Q-Q, Xu Q-Y, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”. Int J Radiat Oncol Biol Phys. 2014;88(5):1120–1128. doi:10.1016/j.ijrobp.2014.01.02224661665
   PubMed Web of Science ®Google Scholar
• Nicosia L, Agolli L, Reverberi C, et al. Salvage radiotherapy with simultaneous integrated boost in non small-cell lung cancer patients with mediastinal relapse after surgery: a pilot study. Radiat Oncol. 2018;13(1):207. doi:10.1186/s13014-018-1155-230352607
   PubMed Web of Science ®Google Scholar